/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2021-06-11 15:23:332021-06-11 15:43:02Ambrx Announces Formation and Members of Scientific Advisory Board
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2021-04-14 08:00:212021-05-28 09:30:18Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2021-03-17 08:00:012021-03-29 18:54:24Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2021-02-23 08:00:022021-03-29 18:53:29Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2021-01-04 08:00:042021-03-29 18:50:38FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2020-12-10 08:00:192021-03-29 18:49:39Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.png00David Anderson/wp-content/uploads/Ambrx_2023-Fullcolor-RGB-1030x228.pngDavid Anderson2020-11-19 08:00:492021-03-29 18:47:49Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics
Ambrx Announces Pricing of Initial Public Offering
Ambrx Announces Formation and Members of Scientific Advisory Board
Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors
Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer
Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics